COMMITTEE | Base Accrual 2010 |
2024 Accrual to date |
Percentage of Base Accrual |
Projected 2024 Accrual |
Projected Increase <Decrease> from Base |
Accrual Last 12 Months |
12 Month Increase <Decrease> from Base |
---|---|---|---|---|---|---|---|
BREAST | 1564 | 119 | 8% | 374 | -1189 | 201 | -1363 |
ERLYTX | 76 | 14 | 18% | 44 | -31 | 41 | -35 |
GI | 479 | 65 | 14% | 204 | -274 | 202 | -277 |
GU | 450 | 170 | 38% | 534 | 84 | 511 | 61 |
GYN | 57 | 0 | 0% | 0 | -57 | 0 | -57 |
LEUK | 150 | 20 | 13% | 62 | -87 | 54 | -96 |
LUNG | 524 | 295 | 56% | 928 | 404 | 774 | 250 |
LYMPH | 172 | 61 | 35% | 191 | 19 | 157 | -15 |
MELAN | 55 | 123 | 224% | 387 | 332 | 437 | 382 |
MMYEL | 147 | 81 | 55% | 254 | 107 | 131 | -16 |
MULT | 0 | 7 | 22 | 22 | 18 | 18 | |
OTHER | 0 | 16 | 50 | 50 | 44 | 44 | |
PREV | 0 | 0 | 0 | 0 | 4 | 4 | |
SXQOL | 0 | 2 | 6 | 6 | 4 | 4 | |
Total | 3674 | 973 | 3056 | -614 | 2578 | -1096 |
COMMITTEE | Base Accrual 2010 |
2024 Accrual to date |
Percentage of Base Accrual |
Projected 2024 Accrual |
Projected Increase <Decrease> from Base |
Accrual Last 12 Months |
12 Month Increase <Decrease> from Base |
---|---|---|---|---|---|---|---|
BREAST | 43 | 0 | 0% | 0 | -43 | 5 | -38 |
CCD | 0 | 278 | 874 | 874 | 940 | 940 | |
ERLYTX | 0 | 5 | 15 | 15 | 8 | 8 | |
GU | 0 | 0 | 0 | 0 | 3 | 3 | |
LEUK | 69 | 0 | 0% | 0 | -69 | 0 | -69 |
LUNG | 43 | 110 | 256% | 346 | 303 | 357 | 314 |
LYMPH | 53 | 0 | 0% | 0 | -53 | 0 | -53 |
MMYEL | 92 | 0 | 0% | 0 | -92 | 0 | -92 |
OTHER | 0 | 7 | 22 | 22 | 9 | 9 | |
PEOLC | 0 | 0 | 0 | 0 | 0 | 0 | |
PREV | 0 | 195 | 613 | 613 | 596 | 596 | |
SURV | 0 | 3 | 9 | 9 | 23 | 23 | |
SXQOL | 888 | 567 | 64% | 1784 | 896 | 1526 | 638 |
Total | 1188 | 1165 | 3663 | 2475 | 3467 | 2279 |
COMMITTEE | Base Accrual 2010 |
2024 Accrual to date |
Percentage of Base Accrual |
Projected 2024 Accrual |
Projected Increase <Decrease> from Base |
Accrual Last 12 Months |
12 Month Increase <Decrease> from Base |
---|---|---|---|---|---|---|---|
BREAST | 1607 | 119 | 7% | 374 | -1232 | 206 | -1401 |
CCD | 0 | 278 | 874 | 874 | 940 | 940 | |
ERLYTX | 76 | 19 | 25% | 59 | -16 | 49 | -27 |
GI | 479 | 65 | 14% | 204 | -274 | 202 | -277 |
GU | 450 | 170 | 38% | 534 | 84 | 514 | 64 |
GYN | 57 | 0 | 0% | 0 | -57 | 0 | -57 |
LEUK | 219 | 20 | 9% | 62 | -156 | 54 | -165 |
LUNG | 567 | 405 | 71% | 1274 | 707 | 1131 | 564 |
LYMPH | 225 | 61 | 27% | 191 | -33 | 157 | -68 |
MELAN | 55 | 123 | 224% | 387 | 332 | 437 | 382 |
MMYEL | 239 | 81 | 34% | 254 | 15 | 131 | -108 |
MULT | 0 | 7 | 22 | 22 | 18 | 18 | |
OTHER | 0 | 23 | 72 | 72 | 53 | 53 | |
PEOLC | 0 | 0 | 0 | 0 | 0 | 0 | |
PREV | 0 | 195 | 613 | 613 | 600 | 600 | |
SURV | 0 | 3 | 9 | 9 | 23 | 23 | |
SXQOL | 888 | 569 | 64% | 1790 | 902 | 1530 | 642 |
Total | 4862 | 2138 | 6719 | 1862 | 6045 | 1183 |
COMMITTEE | Base Accrual 2010 |
2024 Accrual to date |
Percentage of Base Accrual |
Projected 2024 Accrual |
Projected Increase <Decrease> from Base |
Accrual Last 12 Months |
12 Month Increase <Decrease> from Base |
---|---|---|---|---|---|---|---|
BREAST | 1018 | 61 | 6% | 191 | -826 | 129 | -889 |
ERLYTX | 76 | 13 | 17% | 40 | -35 | 33 | -43 |
GI | 421 | 56 | 13% | 176 | -244 | 171 | -250 |
GU | 375 | 143 | 38% | 449 | 74 | 409 | 34 |
GYN | 57 | 0 | 0% | 0 | -57 | 0 | -57 |
LEUK | 122 | 12 | 10% | 37 | -84 | 34 | -88 |
LUNG | 441 | 187 | 42% | 588 | 147 | 522 | 81 |
LYMPH | 129 | 54 | 42% | 169 | 40 | 131 | 2 |
MELAN | 55 | 73 | 133% | 229 | 174 | 265 | 210 |
MMYEL | 85 | 53 | 62% | 166 | 81 | 88 | 3 |
MULT | 0 | 2 | 6 | 6 | 7 | 7 | |
OTHER | 0 | 16 | 50 | 50 | 44 | 44 | |
PREV | 0 | 0 | 0 | 0 | 4 | 4 | |
SXQOL | 0 | 2 | 6 | 6 | 4 | 4 | |
Total | 2779 | 672 | 2107 | -668 | 1841 | -938 |
COMMITTEE | Base Accrual 2010 |
2024 Accrual to date |
Percentage of Base Accrual |
Projected 2024 Accrual |
Projected Increase <Decrease> from Base |
Accrual Last 12 Months |
12 Month Increase <Decrease> from Base |
---|---|---|---|---|---|---|---|
BREAST | 16 | 0 | 0% | 0 | -16 | 5 | -11 |
CCD | 0 | 243 | 764 | 764 | 830 | 830 | |
ERLYTX | 0 | 5 | 15 | 15 | 8 | 8 | |
GU | 0 | 0 | 0 | 0 | 3 | 3 | |
LEUK | 69 | 0 | 0% | 0 | -69 | 0 | -69 |
LUNG | 30 | 68 | 227% | 213 | 183 | 195 | 165 |
LYMPH | 53 | 0 | 0% | 0 | -53 | 0 | -53 |
MMYEL | 92 | 0 | 0% | 0 | -92 | 0 | -92 |
OTHER | 0 | 7 | 22 | 22 | 9 | 9 | |
PEOLC | 0 | 0 | 0 | 0 | 0 | 0 | |
PREV | 0 | 133 | 418 | 418 | 401 | 401 | |
SURV | 0 | 2 | 6 | 6 | 16 | 16 | |
SXQOL | 750 | 356 | 47% | 1120 | 370 | 987 | 237 |
Total | 1010 | 814 | 2558 | 1548 | 2454 | 1444 |
COMMITTEE | Base Accrual 2010 |
2024 Accrual to date |
Percentage of Base Accrual |
Projected 2024 Accrual |
Projected Increase <Decrease> from Base |
Accrual Last 12 Months |
12 Month Increase <Decrease> from Base |
---|---|---|---|---|---|---|---|
BREAST | 1034 | 61 | 6% | 191 | -842 | 134 | -900 |
CCD | 0 | 243 | 764 | 764 | 830 | 830 | |
ERLYTX | 76 | 18 | 24% | 56 | -19 | 41 | -35 |
GI | 421 | 56 | 13% | 176 | -244 | 171 | -250 |
GU | 375 | 143 | 38% | 449 | 74 | 412 | 37 |
GYN | 57 | 0 | 0% | 0 | -57 | 0 | -57 |
LEUK | 191 | 12 | 6% | 37 | -153 | 34 | -157 |
LUNG | 471 | 255 | 54% | 802 | 331 | 717 | 246 |
LYMPH | 182 | 54 | 30% | 169 | -12 | 131 | -51 |
MELAN | 55 | 73 | 133% | 229 | 174 | 265 | 210 |
MMYEL | 177 | 53 | 30% | 166 | -10 | 88 | -89 |
MULT | 0 | 2 | 6 | 6 | 7 | 7 | |
OTHER | 0 | 23 | 72 | 72 | 53 | 53 | |
PEOLC | 0 | 0 | 0 | 0 | 0 | 0 | |
PREV | 0 | 133 | 418 | 418 | 405 | 405 | |
SURV | 0 | 2 | 6 | 6 | 16 | 16 | |
SXQOL | 750 | 358 | 48% | 1126 | 376 | 991 | 241 |
Total | 3789 | 1486 | 4667 | 884 | 4295 | 506 |
COMMITTEE | Base Accrual 2010 |
2024 Accrual to date |
Percentage of Base Accrual |
Projected 2024 Accrual |
Projected Increase <Decrease> from Base |
Accrual Last 12 Months |
12 Month Increase <Decrease> from Base |
---|---|---|---|---|---|---|---|
BREAST | 65 | 118 | 182% | 371 | 306 | 188 | 123 |
CCD | 0 | 278 | 874 | 874 | 940 | 940 | |
ERLYTX | 0 | 0 | 0 | 0 | 1 | 1 | |
GI | 81 | 3 | 4% | 9 | -71 | 26 | -55 |
GU | 215 | 142 | 66% | 446 | 231 | 434 | 219 |
LEUK | 0 | 15 | 47 | 47 | 36 | 36 | |
LUNG | 53 | 88 | 166% | 276 | 223 | 245 | 192 |
LYMPH | 7 | 33 | 471% | 103 | 96 | 81 | 74 |
MELAN | 0 | 0 | 0 | 0 | 0 | 0 | |
MMYEL | 0 | 80 | 251 | 251 | 130 | 130 | |
OTHER | 0 | 4 | 12 | 12 | 15 | 15 | |
PEOLC | 0 | 0 | 0 | 0 | 0 | 0 | |
PREV | 0 | 142 | 446 | 446 | 437 | 437 | |
SURV | 0 | 3 | 9 | 9 | 23 | 23 | |
SXQOL | 880 | 569 | 65% | 1790 | 910 | 1530 | 650 |
Total | 1301 | 1475 | 4634 | 3334 | 4086 | 2785 |
Comm. | Phase | Study | Stat Center |
Open Date |
Months Open |
Total Regs |
Accrual Goal |
Monthly Accrual Rate |
Date of Expected Closure or Temporary Closure |
---|---|---|---|---|---|---|---|---|---|
BREAST | II | NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv | NRG | 13APR2017:00:00:00 | 7 | Dec-2022 Temp Close | |||
S1706 Breast, Inflammatory, RT +/- Olaparib | SWOG | 12SEP2018:00:00:00 | 67 | 153 | 300 | 2.3 | Jun-2029 | ||
S2007 Breast, Brain Mets, Sacituzumab Govitecan | SWOG | 15DEC2020:00:00:00 | 40 | 24 | 44 | 0.3 | Mar-2029 | ||
II-III | NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA | NRG | 24DEC2014:00:00:00 | 1 | May-2022 Temp Close | ||||
III | A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib | ALLIANCE | 06JAN2021:00:00:00 | 42 | 1.2 | ||||
A012103 Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab | ALLIANCE | 03MAY2023:00:00:00 | 5 | 0.5 | |||||
MA39 BREAST, Node-Pos, Reg RT vs No Reg RT | CCTG | 30MAY2018:00:00:00 | 28 | 1.2 | |||||
NRGBR007 Breast, Stg I, De-Escalation of Breast RT | NRG | 07JUN2021:00:00:00 | 8 | 0.3 | |||||
NRGBR009 Breast, EarlyStg, Adjuvant Chemo | NRG | 31AUG2023:00:00:00 | 3 | 0.5 | |||||
S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva | SWOG | 30OCT2023:00:00:00 | 5 | 8 | 960 | 1.4 | > 15 Yrs | ||
S2212 Breast, TNBC, Neoadj Chemo + Pembro | SWOG | 21JUL2023:00:00:00 | 9 | 112 | 2400 | 17.5 | Feb-2035 | ||
CCD | III | A191901 Brst, Text/Motivational Intervention ET Adher | ALLIANCE | 10DEC2020:00:00:00 | 39 | 0.0 | |||
S1703 Met Breast, STM-monitoring v Usual Care | SWOG | 16JUL2018:00:00:00 | 69 | 333 | 739 | 5.0 | Jan-2031 | ||
S1912CD CREDIT, Fin Counseling to reduce Fin Hardship | SWOG | 26JUL2021:00:00:00 | 32 | 227 | 326 | 16.7 | Sep-2024 | ||
S2108CD Genomic Tumor Board vs Usual Practice | SWOG | 22AUG2022:00:00:00 | 20 | 952 | 1182 | 51.5 | Aug-2024 | ||
OTHER | A231602C Blood Cancer, Assess Financial Difficulty | ALLIANCE | 15MAR2019:00:00:00 | 4 | Feb-2021 Temp Close | ||||
ACCL16N1 Guideline Consistent Treatment AYA ALL | COG | 18DEC2017:00:00:00 | 54 | Aug-2022 Temp Close | |||||
NHLBIMDS LEUK, National MDS Study | ECOG-ACRIN | 05APR2016:00:00:00 | 247 | 3.8 | |||||
ERLYTX | II | A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib | ALLIANCE | 28AUG2015:00:00:00 | 8 | 0.0 | |||
EAY191-S3 ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib | SWOG | 06MAR2023:00:00:00 | 13 | 1 | 33 | 0.0 | > 15 Yrs | ||
EAY191A3 ComboMATCH-RAS-Mutant, All Stg, Palbo+Benim | ALLIANCE | 15NOV2023:00:00:00 | 2 | 0.4 | |||||
EAY191E4 ComboMATCH-Pr. Tax-Tx Tumors, Pac+Nilotinib | ECOG-ACRIN | 07JUN2023:00:00:00 | 3 | 0.2 | |||||
II-III | S2012 Small Cell NEC, Stg IV, Combo Chemo +/- Atezo | SWOG | 02DEC2021:00:00:00 | 28 | 44 | 189 | 3.3 | Nov-2027 | |
III | AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult | COG | 08MAY2017:00:00:00 | 2 | 0.0 | ||||
OTHER | EAY191 ComboMATCH | ECOG-ACRIN | 06MAR2023:00:00:00 | 8 | 0.8 | ||||
GI | II | A022001 PANC, METS, Lu 177 Dotatate PRRT vs CAPTEM | ALLIANCE | 16MAR2022:00:00:00 | 2 | 0.2 | |||
A022104 Rectal, Loc Adv, Triplet vs Doublet Chemo | ALLIANCE | 09NOV2022:00:00:00 | 51 | 6.0 | |||||
EA2182 Anal, Erly, DECREASE | ECOG-ACRIN | 12NOV2019:00:00:00 | 13 | 0.0 | |||||
EA2192 Panc, APOLLO | ECOG-ACRIN | 29APR2021:00:00:00 | 2 | 0.2 | |||||
S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | SWOG | 16DEC2019:00:00:00 | 52 | 32 | 94 | 0.3 | > 15 Yrs | ||
S2001 Rando II, Mets Pancreas , BRCA1/2, Comb Chemo | SWOG | 04DEC2020:00:00:00 | 40 | 47 | 88 | 0.5 | Jan-2031 | ||
S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs | SWOG | 14OCT2021:11:13:50 | 30 | 41 | 154 | 2.3 | Apr-2028 | ||
S2107 Colorectal, BRAF mut, Enc + CET +/-Nivo | SWOG | 06JUN2022:10:01:28 | 22 | 61 | 84 | 3.7 | Oct-2024 | ||
II-III | A022004 Colon, Stg II-III, Encor+Cetux vs SOC | ALLIANCE | 30MAY2023:00:00:00 | 0 | 0.0 | ||||
EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab | ECOG-ACRIN | 17JAN2019:00:00:00 | 6 | 0.0 | |||||
EA2197 Gal, Rando Perioperative TX | ECOG-ACRIN | 22DEC2020:00:00:00 | 5 | 0.2 | |||||
NRGGI008 Colon, Stg III, Adj Chemo | NRG | 10MAR2022:00:00:00 | 18 | 1.0 | |||||
III | A021806 Pancreas, Perioperative vs Adjuvant Chemo | ALLIANCE | 01JUL2020:00:00:00 | 29 | 0.7 | ||||
A022102 Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/ Nivo | ALLIANCE | 11JAN2023:00:00:00 | 10 | 1.0 | |||||
EA2176 Anal, Met, Immune Check Pt Inhibition + Chemo | ECOG-ACRIN | 15OCT2020:00:00:00 | 28 | 1.0 | |||||
NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy | NRG | 07NOV2017:00:00:00 | 77 | 15 | 0.0 | ||||
GU | II | A031701 Bladder, ddGC for MIBC with DDR Tumor Alt | ALLIANCE | 01AUG2018:00:00:00 | 20 | 0.3 | |||
A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) | ALLIANCE | 12APR2019:00:00:00 | 26 | 0.0 | |||||
A031801 GU, mRCC, Cabozantinib +/- Radium-223 | ALLIANCE | 13DEC2019:00:00:00 | 14 | 0.7 | |||||
A031803 Blad, NMIBC, Gemcitabine + MK-3475 | ALLIANCE | 06JAN2020:00:00:00 | 43 | 0.5 | |||||
EA8171 PROS, newly diagnosed, mpMRI for pre-op stagi | ECOG-ACRIN | 09JUL2018:00:00:00 | 87 | 0.0 | |||||
NRGGU011 Pros, Dbl Blinded RT +/- Androgen Dep Tx | NRG | 08DEC2021:00:00:00 | 9 | 1.0 | |||||
NRGGU012 Renal, Stg IV, Stereo Abl Rad Therapy | NRG | 30JUN2022:00:00:00 | 2 | 0.3 | |||||
S2200 pRCC, Adv, Cabo +/- Atezo | SWOG | 19SEP2022:00:00:00 | 19 | 16 | 200 | 1.5 | Jun-2034 | ||
S2210 Pros, High Risk, BRCA, Neoadj Carbo | SWOG | 14AUG2023:00:00:00 | 8 | 1 | 44 | 0.2 | > 15 Yrs | ||
II-III | A032103 Urothelial, All Stg, MRD-Based Adj Tx | ALLIANCE | 09JAN2024:00:00:00 | 0 | 0.0 | ||||
EA8192 Blad, High Grade UTUC, Durv + Chemo | ECOG-ACRIN | 06MAY2021:00:00:00 | 3 | 0.2 | |||||
III | A031704 RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo | ALLIANCE | 09MAY2019:00:00:00 | 126 | 2.2 | ||||
EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT | ECOG-ACRIN | 08SEP2017:00:00:00 | 12 | 0.0 | |||||
EA8191 Pros, Local vs Systemic Thrpy | ECOG-ACRIN | 08OCT2020:00:00:00 | 29 | 1.2 | |||||
EA8212 Blad, NMIBC, BRIDGE | ECOG-ACRIN | 01DEC2022:00:00:00 | 104 | 9.2 | |||||
NRGGU008 Pros,Node+, Abiraterone acetate + Apalutamide | NRG | 05MAR2020:00:00:00 | 13 | 0.7 | |||||
NRGGU009 Pros, PREDICT-RT | NRG | 15DEC2020:00:00:00 | 46 | 3.0 | |||||
NRGGU010 Pros, Parallel De-Intens & Intens Trials | NRG | 03NOV2021:00:00:00 | 31 | 1.5 | |||||
S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum | SWOG | 17SEP2018:00:00:00 | 67 | 790 | 1273 | 10.7 | Jan-2028 | ||
S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only | SWOG | 16NOV2020:00:00:00 | 41 | 91 | 332 | 2.8 | May-2031 | ||
S1937 Blad, Mets, Eribulin + Gem vs SOC | SWOG | 16FEB2021:00:00:00 | 38 | 27 | 184 | 0.7 | > 15 Yrs | ||
LEUK | I-II | EA9152 ALL, T/B-Cell, Venetoclax + Vincristine | ECOG-ACRIN | 26APR2018:00:00:00 | 3 | 0.2 | |||
S1905 T-ALL/T-LBL, Rel/Ref, OBI-3424 | SWOG | 17AUG2020:00:00:00 | 44 | 14 | 64 | 0.2 | > 15 Yrs | ||
II | A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat | ALLIANCE | 16NOV2018:00:00:00 | 5 | 0.2 | ||||
A042001 B-Cell ALL, Inotuzunab+chemo v Standard chemo | ALLIANCE | 27FEB2023:00:00:00 | 2 | 0.2 | |||||
EA9171 CML, Anti-PD-1 Pembrolizumab + TKIs | ECOG-ACRIN | 03OCT2018:00:00:00 | 4 | 0.3 | |||||
EA9213 T-ALL, dara-hyal for chemo refractory MRD | ECOG-ACRIN | 16JUN2022:00:00:00 | 3 | 0.2 | |||||
II-III | A041701 AML, Age 60+, Conv Chemo +/- Uproleselan | ALLIANCE | 16JAN2019:00:00:00 | 38 | 0.0 | ||||
III | A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo | ALLIANCE | 01JUN2017:00:00:00 | 44 | 0.0 | ||||
EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab | ECOG-ACRIN | 14OCT2020:00:00:00 | 33 | 0.7 | |||||
S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O | SWOG | 14DEC2020:00:00:00 | 40 | 100 | 247 | 3.2 | Feb-2028 | ||
LUNG | II | EA5162 NSCLS,StgIV/IIB,EGFR exon20 insertion,AZD9291 | ECOG-ACRIN | 05APR2018:00:00:00 | 1 | 0.0 | |||
S1900E KRAS G12C: Sotorasib (AMG 510) | SWOG | 02APR2021:00:00:00 | 36 | 112 | 116 | 1.7 | Jun-2024 | ||
S1900G EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu | SWOG | 03APR2023:00:00:00 | 12 | 11 | 66 | 0.7 | Feb-2031 | ||
S1900K MET Exon 14: Tepotinib +/- Ramucirumab | SWOG | 18DEC2023:00:00:00 | 4 | 0 | 56 | 0.0 | > 15 Yrs | ||
S1933 NSCLC, Stg II-III, RT + Atezo | SWOG | 15JUN2020:10:15:53 | 46 | 36 | 47 | 1.0 | Feb-2025 | ||
II-III | A082002 Lung, Adv, Systemic Tx +/- SBRT | ALLIANCE | 21DEC2021:00:00:00 | 4 | 0.2 | ||||
III | A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO | ALLIANCE | 03JUN2020:00:00:00 | 75 | 1.3 | ||||
E4512 ALCHEMIST2, ALK mut, Crizotinib | ECOG-ACRIN | 18AUG2014:00:00:00 | 22 | 0.5 | |||||
EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 | ECOG-ACRIN | 22OCT2020:00:00:00 | 14 | 0.7 | |||||
NRGLU008 Lung NSCL, StgII-III, StereoBodyRad/MedChemo | NRG | 10MAY2023:00:00:00 | 1 | 0.2 | |||||
S1827 SCLC, MRI Surveillance +/- PCI | SWOG | 10JAN2020:00:00:00 | 51 | 213 | 668 | 5.0 | Oct-2031 | ||
S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo | SWOG | 25MAR2020:00:00:00 | 49 | 350 | 480 | 13.3 | Jan-2025 | ||
S2302 NSCLC, Stg IV or Recur, Ramu + Pembro vs SoC | SWOG | 06MAR2023:08:56:25 | 13 | 445 | 700 | 44.8 | Sep-2024 | ||
OTHER | A151216 ALCHEMIST0 - screening | ALLIANCE | 18AUG2014:00:00:00 | 975 | 2.2 | ||||
LUNGMAP NSCLC, Adv, Master | SWOG | 28JAN2019:00:00:00 | 62 | 3350 | 24.2 | ||||
LYMPH | I-II | E4412 HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin | ECOG-ACRIN | 24JAN2014:00:00:00 | 20 | 0.0 | |||
II | A051902 PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P | ALLIANCE | 30JUL2021:00:00:00 | 4 | 0.5 | ||||
S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob | SWOG | 10AUG2017:00:00:00 | 80 | 77 | 95 | 0.5 | Mar-2027 | ||
S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation | SWOG | 23FEB2023:11:55:36 | 14 | 41 | 396 | 3.7 | Apr-2032 | ||
S2207 LBCL, Transplant Inelig, Targeted Tx + Tafa | SWOG | 30JUN2023:11:49:39 | 9 | 13 | 227 | 2.0 | Feb-2033 | ||
II-III | A051701 LYMPH, MYC/BC2 DHL&DEL, R-chemo+/-Venetoclax | ALLIANCE | 07AUG2019:00:00:00 | 34 | Dec-2023 Temp Close | ||||
S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP | SWOG | 19MAR2021:00:00:00 | 37 | 96 | 422 | 4.0 | Jan-2031 | ||
III | A052101 Lymph, Stg I-IV, Cont v Intermittent Zanub | ALLIANCE | 08SEP2023:00:00:00 | 5 | 0.8 | ||||
AHOD2131 cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy | COG | 28APR2023:00:00:00 | 17 | 2.0 | |||||
ANHL1931 PMBCL, Chemo-Immunotherapy +/- Nivo | COG | 07JUN2021:00:00:00 | 20 | 1.2 | |||||
EA4151 Lymph, AHCT +/-Ritux, MRD Neg | ECOG-ACRIN | 29AUG2017:00:00:00 | 127 | 1.3 | |||||
MELAN | II | A091903 Melan, Resected Mucosal, Adj Nivo +/- Cabo | ALLIANCE | 01JUN2022:00:00:00 | 1 | 0.0 | |||
EA6192 Melan, Adv, Erly Discont of Antibdy Thrpy | ECOG-ACRIN | 27AUG2020:00:00:00 | 8 | 0.0 | |||||
EA6194 Melan, Stage IIIB-D, Pembro +/- CMP-001 | ECOG-ACRIN | 19MAR2021:00:00:00 | 4 | 0.7 | |||||
S2000 MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo | SWOG | 23SEP2020:00:00:00 | 43 | 32 | 35 | 0.5 | Sep-2024 | ||
II-III | EA6141 Melan, Adv, Nivolumab+Ipi ± Sargmostim | ECOG-ACRIN | 10SEP2015:00:00:00 | 60 | 0.7 | ||||
III | EA6174 Merkel, Adjuvant Pembrolizumab vs Observation | ECOG-ACRIN | 23JUL2018:00:00:00 | 53 | 0.0 | ||||
S2015 MELAN, Stg I-II, 1cm v 2cm excision margins | MASC | 08APR2022:00:00:00 | 583 | 31.8 | |||||
MMYEL | II | EAA173 MYEL, SMM, Rd +/- Daratumumab | ECOG-ACRIN | 30APR2019:00:00:00 | 27 | 0.5 | |||
III | EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) | ECOG-ACRIN | 27OCT2020:00:00:00 | 35 | 1.3 | ||||
S1803 MM, Maintenance, Len vs Len/Dara | SWOG | 27JUN2019:00:00:00 | 57 | 1111 | 1100 | 11.2 | Apr-2024 | ||
S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D | SWOG | 30MAY2023:00:00:00 | 10 | 20 | 510 | 3.2 | Feb-2037 | ||
S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT | SWOG | 01DEC2023:00:00:00 | 4 | 0 | 338 | 0.0 | > 15 Yrs | ||
MULT | II | S2101 Melan or HNSCC, Adv, Cabo + Nivo | SWOG | 14OCT2022:10:48:23 | 18 | 34 | 220 | 1.2 | Jul-2037 |
OTHER | I | NRGGY022 Mult Site/Stg, Carboplat Clearance Predict | NRG | 18NOV2019:00:00:00 | 3 | 0.5 | |||
II | A071701 BRAIN, Met, Geno-guided trial | ALLIANCE | 15AUG2019:00:00:00 | 2 | 0.0 | ||||
A071702 BRAIN, Blockade Tx in Recurrent Glioblastoma | ALLIANCE | 30OCT2020:00:00:00 | 0 | 0.0 | |||||
A092107 DDLPS. Palbocicli v Palbociclib+Cemiplimab | ALLIANCE | 24MAR2023:00:00:00 | 5 | 0.8 | |||||
EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp | ECOG-ACRIN | 29MAR2016:00:00:00 | 21 | 0.0 | |||||
EA3191 HN, High Risk HNSCC, Adj +/- Pembro | ECOG-ACRIN | 08JAN2021:00:00:00 | 7 | 0.2 | |||||
NRGHN010 HER2+ SGC, T-DM1 vs TH | NRG | 30SEP2022:00:00:00 | 4 | 0.3 | |||||
II-III | A092104 Uter,Adv, Olaparib+Temozolomide vs Inv Choice | ALLIANCE | 09DEC2022:00:00:00 | 6 | 1.0 | ||||
EA3161 HNC, HPV+ OPCA, (cisplatin+RT) +/- Nivo | ECOG-ACRIN | 20JUN2019:00:00:00 | 61 | 1.3 | |||||
NRGHN005 HN, early stg P16-pos, randomize de-intensifi | NRG | 10JUL2019:00:00:00 | 8 | 0.0 | |||||
NRGHN006 HN, Erly Stg, Biopsy vs Dissection | NRG | 08JUL2020:00:00:00 | 2 | 0.0 | |||||
NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN | NRG | 27OCT2021:00:00:00 | 14 | 1.0 | |||||
R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux | NRG | 18MAR2013:00:00:00 | 6 | 0.0 | |||||
III | AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo | COG | 30JUL2018:00:00:00 | 4 | Temp Close | ||||
ARST2031 RMS, Stg IV, VINO-AC+VINO-CPO vs VAC+VINO-CPO | COG | 13SEP2021:00:00:00 | 1 | 0.0 | |||||
CCTGHN11 HN, All Stg, Guided Elec Contra Neck Tx | CCTG | 29SEP2022:00:00:00 | 1 | 0.2 | |||||
N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC | ALLIANCE | 22SEP2009:00:00:00 | 12 | 0.0 | |||||
NRGBN003 Mening, Grd II, Observation vs Irradiation | NRG | 14JUN2017:00:00:00 | 3 | 0.0 | |||||
NRGBN011 Brain, Lomustine + Temo vs Temo | NRG | 29NOV2021:00:00:00 | 4 | 0.0 | |||||
NRGBN012 Brain, Pre- vs Post-Op Stereotactic Radiosurg | NRG | 31AUG2022:00:00:00 | 1 | 0.0 | |||||
NRGGY019 Ovar, Stg II-IV, Pac/Carb/Let vs. Let Mono | NRG | 26AUG2019:00:00:00 | 1 | 0.2 | |||||
OTHER | A151804 irAEs, National Biorepository to Adv Studies | ALLIANCE | 31JAN2020:00:00:00 | 24 | 0.7 | ||||
PREV | II | EA2185 Panc, Impact of Panc Cyst Surveillance | ECOG-ACRIN | 16JAN2020:00:00:00 | 19 | 0.5 | |||
EA8184 Pros, Dbl Blind GTC vs Placebo | ECOG-ACRIN | 20MAY2021:00:00:00 | 4 | 0.2 | |||||
III | EA1151 Prev, Tomosynthesis Mammographic Screening | ECOG-ACRIN | 06JUL2017:00:00:00 | 2462 | 13.8 | ||||
NRGCC005 Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs | NRG | 06OCT2021:00:00:00 | 4 | 0.7 | |||||
OTHER | A212102 Blind Ref Set for Multicancer Early Detection | ALLIANCE | 01AUG2022:00:00:00 | 94 | 6.2 | ||||
NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO | NRG | 23JUN2020:00:00:00 | 9 | 0.5 | |||||
S1823 GCT, Obs. Cohort, miRNA371 | SWOG | 01JUN2020:13:00:37 | 46 | 940 | 956 | 17.3 | Apr-2024 | ||
PILOT | S1904 Breast, Decision making for chemoprevention | SWOG | 01SEP2020:00:00:00 | 43 | 398 | 415 | 12.2 | May-2024 | |
SURV | III | A211901 Cancer survivors who smoke, txt cessation | ALLIANCE | 01DEC2021:00:00:00 | 5 | 0.7 | |||
S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol | SWOG | 15SEP2017:00:00:00 | 310 | 817 | Feb-2024 Temp Close | ||||
SXQOL | II-III | A221805 Colorectal, Duloxetine for Oxaliplatin CIPN | ALLIANCE | 01MAY2020:00:00:00 | 8 | 0.0 | |||
III | A222004 Mult, Olanza vs Megestrol for Anorexia | ALLIANCE | 15OCT2021:00:00:00 | 3 | 0.2 | ||||
ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis | COG | 14AUG2023:00:00:00 | 2 | 0.3 | |||||
NRGCC010 Endo, Stg I, LN Map for LE Limb Dysfunction | NRG | 19SEP2022:00:00:00 | 7 | 0.3 | |||||
NRGCC011 Breast, Survivors, Cog Training | NRG | 02FEB2024:00:00:00 | 0 | ||||||
S2010 ASPEN: Brst, Stg I-III, ASM vs Pt Ed | SWOG | 17JAN2023:00:00:00 | 15 | 277 | 540 | 28.2 | Jan-2025 | ||
S2205 ICE COMPRESS: Reduction of CIPN from Taxanes | SWOG | 16MAR2023:00:00:00 | 13 | 127 | 777 | 14.8 | Nov-2027 | ||
OTHER | S2013 I-CHECKIT: ICI toxicity risk prediction study | SWOG | 16AUG2021:00:00:00 | 32 | 2043 | 2062 | 90.0 | Apr-2024 | |
PILOT | EAQ202 Improving AYA PROs in EA Trials | ECOG-ACRIN | 28OCT2021:00:00:00 | 43 | 0.0 | ||||
Accrual goals assume studies are not terminated early as a result of interim analysis. Studies may have accrual objectives specific to subsets of patients and are not reflected in this report. Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months. Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months. |
Phase | Comm. | Int grp |
Stat Center |
Study | NCIPROTO | CA Cntrl Study |
Temp Close |
---|---|---|---|---|---|---|---|
OTHER | CCD | Y | COG | ACCL16N1 Guideline Consistent Treatment AYA ALL | ACCL16N1CD | Y | Y |
Y | ECOG-ACRIN | NHLBIMDS LEUK, National MDS Study | NHLBI-MDS | Y | |||
Y | ALLIANCE | A231602C Blood Cancer, Assess Financial Difficulty | A231602CD | Y | Y | ||
ERLYTX | Y | ECOG-ACRIN | EAY191 ComboMATCH | EAY191 | N | ||
LUNG | Y | SWOG | LUNGMAP NSCLC, Adv, Master | LUNGMAP | N | ||
Y | ALLIANCE | A151216 ALCHEMIST0 - screening | A151216 | N | |||
OTHER | Y | ALLIANCE | A151804 irAEs, National Biorepository to Adv Studies | A151804 | N | ||
PREV | Y | SWOG | S1823 GCT, Obs. Cohort, miRNA371 | S1823 | Y | ||
Y | ALLIANCE | A212102 Blind Ref Set for Multicancer Early Detection | A212102 | Y | |||
Y | NRG | NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO | NRG-CC008 | Y | |||
SXQOL | Y | SWOG | S2013 I-CHECKIT: ICI toxicity risk prediction study | S2013 | Y | ||
I | OTHER | Y | NRG | NRGGY022 Mult Site/Stg, Carboplat Clearance Predict | NRG-GY022 | N | |
I-II | LEUK | Y | SWOG | S1905 T-ALL/T-LBL, Rel/Ref, OBI-3424 | S1905 | N | |
Y | ECOG-ACRIN | EA9152 ALL, T/B-Cell, Venetoclax + Vincristine | EA9152 | N | |||
LYMPH | Y | ECOG-ACRIN | E4412 HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin | E4412 | N | ||
II | BREAST | Y | SWOG | S1706 Breast, Inflammatory, RT +/- Olaparib | S1706 | Y | |
Y | SWOG | S2007 Breast, Brain Mets, Sacituzumab Govitecan | S2007 | N | |||
Y | NRG | NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv | NRG-BR005 | N | Y | ||
ERLYTX | Y | SWOG | EAY191-S3 ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib | EAY191-S3 | N | ||
Y | ALLIANCE | A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib | A071401 | N | |||
Y | ECOG-ACRIN | EAY191E4 ComboMATCH-Pr. Tax-Tx Tumors, Pac+Nilotinib | EAY191-E4 | N | |||
Y | ALLIANCE | EAY191A3 ComboMATCH-RAS-Mutant, All Stg, Palbo+Benim | EAY191-A3 | N | |||
GI | EA2192 Panc, APOLLO | N | |||||
Y | SWOG | S2001 Rando II, Mets Pancreas , BRCA1/2, Comb Chemo | S2001 | N | |||
Y | SWOG | S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | S1922 | N | |||
Y | SWOG | S2107 Colorectal, BRAF mut, Enc + CET +/-Nivo | S2107 | N | |||
Y | SWOG | S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs | S2104 | N | |||
Y | ALLIANCE | A022104 Rectal, Loc Adv, Triplet vs Doublet Chemo | A022104 | N | |||
Y | ECOG-ACRIN | EA2182 Anal, Erly, DECREASE | EA2182 | Y | |||
Y | ALLIANCE | A022001 PANC, METS, Lu 177 Dotatate PRRT vs CAPTEM | A022001 | Y | |||
GU | Y | SWOG | S2200 pRCC, Adv, Cabo +/- Atezo | S2200 | N | ||
Y | SWOG | S2210 Pros, High Risk, BRCA, Neoadj Carbo | S2210 | N | |||
Y | ECOG-ACRIN | EA8171 PROS, newly diagnosed, mpMRI for pre-op stagi | EA8171 | N | |||
Y | ALLIANCE | A031701 Bladder, ddGC for MIBC with DDR Tumor Alt | A031701 | N | |||
Y | ALLIANCE | A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) | A031702 | N | |||
Y | ALLIANCE | A031803 Blad, NMIBC, Gemcitabine + MK-3475 | A031803 | N | |||
Y | NRG | NRGGU011 Pros, Dbl Blinded RT +/- Androgen Dep Tx | NRG-GU011 | Y | |||
Y | NRG | NRGGU012 Renal, Stg IV, Stereo Abl Rad Therapy | NRG-GU012 | N | |||
Y | ALLIANCE | A031801 GU, mRCC, Cabozantinib +/- Radium-223 | A031801 | Y | |||
LEUK | A042001 B-Cell ALL, Inotuzunab+chemo v Standard chemo | N | |||||
EA9213 T-ALL, dara-hyal for chemo refractory MRD | N | ||||||
Y | ECOG-ACRIN | EA9171 CML, Anti-PD-1 Pembrolizumab + TKIs | EA9171 | N | |||
Y | ALLIANCE | A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat | A041703 | N | |||
LUNG | Y | SWOG | S1933 NSCLC, Stg II-III, RT + Atezo | S1933 | N | ||
Y | SWOG | S1900G EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu | S1900G | N | |||
Y | SWOG | S1900K MET Exon 14: Tepotinib +/- Ramucirumab | S1900K | N | |||
Y | SWOG | S1900E KRAS G12C: Sotorasib (AMG 510) | S1900E | N | |||
Y | ECOG-ACRIN | EA5162 NSCLS,StgIV/IIB,EGFR exon20 insertion,AZD9291 | EA5162 | N | |||
LYMPH | Y | SWOG | S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob | S1608 | N | ||
Y | SWOG | S2207 LBCL, Transplant Inelig, Targeted Tx + Tafa | S2207 | Y | |||
Y | SWOG | S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation | S2114 | N | |||
Y | ALLIANCE | A051902 PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P | A051902 | N | |||
MELAN | A091903 Melan, Resected Mucosal, Adj Nivo +/- Cabo | N | |||||
Y | SWOG | S2000 MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo | S2000 | N | |||
Y | ECOG-ACRIN | EA6194 Melan, Stage IIIB-D, Pembro +/- CMP-001 | EA6194 | N | |||
Y | ECOG-ACRIN | EA6192 Melan, Adv, Erly Discont of Antibdy Thrpy | EA6192 | N | |||
MMYEL | Y | ECOG-ACRIN | EAA173 MYEL, SMM, Rd +/- Daratumumab | EAA173 | Y | ||
MULT | Y | SWOG | S2101 Melan or HNSCC, Adv, Cabo + Nivo | S2101 | N | ||
OTHER | A071702 BRAIN, Blockade Tx in Recurrent Glioblastoma | N | |||||
Y | ECOG-ACRIN | EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp | EA3132 | N | |||
Y | NRG | NRGHN010 HER2+ SGC, T-DM1 vs TH | NRG-HN010 | N | |||
Y | ALLIANCE | A071701 BRAIN, Met, Geno-guided trial | A071701 | N | |||
Y | ALLIANCE | A092107 DDLPS. Palbocicli v Palbociclib+Cemiplimab | A092107 | N | |||
Y | ECOG-ACRIN | EA3191 HN, High Risk HNSCC, Adj +/- Pembro | EA3191 | N | |||
PREV | EA8184 Pros, Dbl Blind GTC vs Placebo | Y | |||||
Y | ECOG-ACRIN | EA2185 Panc, Impact of Panc Cyst Surveillance | EA2185 | Y | |||
PILOT | PREV | Y | SWOG | S1904 Breast, Decision making for chemoprevention | S1904 | Y | |
SXQOL | Y | ECOG-ACRIN | EAQ202 Improving AYA PROs in EA Trials | EAQ202 | Y | ||
II-III | BREAST | Y | NRG | NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA | NRG-BR002 | N | Y |
ERLYTX | Y | SWOG | S2012 Small Cell NEC, Stg IV, Combo Chemo +/- Atezo | S2012 | N | ||
GI | A022004 Colon, Stg II-III, Encor+Cetux vs SOC | Y | |||||
Y | ECOG-ACRIN | EA2197 Gal, Rando Perioperative TX | EA2197 | N | |||
Y | ECOG-ACRIN | EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab | EA2174 | N | |||
Y | NRG | NRGGI008 Colon, Stg III, Adj Chemo | NRG-GI008 | N | |||
GU | A032103 Urothelial, All Stg, MRD-Based Adj Tx | Y | |||||
Y | ECOG-ACRIN | EA8192 Blad, High Grade UTUC, Durv + Chemo | EA8192 | N | |||
LEUK | Y | ALLIANCE | A041701 AML, Age 60+, Conv Chemo +/- Uproleselan | A041701 | N | ||
LUNG | Y | ALLIANCE | A082002 Lung, Adv, Systemic Tx +/- SBRT | A082002 | Y | ||
LYMPH | Y | SWOG | S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP | S1918 | Y | ||
Y | ALLIANCE | A051701 LYMPH, MYC/BC2 DHL&DEL, R-chemo+/-Venetoclax | A051701 | N | Y | ||
MELAN | Y | ECOG-ACRIN | EA6141 Melan, Adv, Nivolumab+Ipi ± Sargmostim | EA6141 | N | ||
OTHER | Y | NRG | NRGHN005 HN, early stg P16-pos, randomize de-intensifi | NRG-HN005 | Y | ||
Y | ECOG-ACRIN | EA3161 HNC, HPV+ OPCA, (cisplatin+RT) +/- Nivo | EA3161 | N | |||
Y | NRG | R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux | RTOG-1216 | Y | |||
Y | NRG | NRGHN006 HN, Erly Stg, Biopsy vs Dissection | NRG-HN006 | Y | |||
Y | NRG | NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN | NRG-HN009 | Y | |||
Y | ALLIANCE | A092104 Uter,Adv, Olaparib+Temozolomide vs Inv Choice | A092104 | N | |||
SXQOL | Y | ALLIANCE | A221805 Colorectal, Duloxetine for Oxaliplatin CIPN | A221805 | Y | ||
III | BREAST | Y | SWOG | S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva | S2206 | Y | |
Y | SWOG | S2212 Breast, TNBC, Neoadj Chemo + Pembro | S2212 | Y | |||
Y | CCTG | MA39 BREAST, Node-Pos, Reg RT vs No Reg RT | CCTG MA.39 | Y | |||
Y | ALLIANCE | A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib | A011801 | Y | |||
Y | ALLIANCE | A012103 Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab | A012103 | Y | |||
Y | NRG | NRGBR009 Breast, EarlyStg, Adjuvant Chemo | NRG-BR009 | Y | |||
Y | NRG | NRGBR007 Breast, Stg I, De-Escalation of Breast RT | NRG-BR007 | Y | |||
CCD | Y | SWOG | S1703 Met Breast, STM-monitoring v Usual Care | S1703 | Y | ||
Y | SWOG | S2108CD Genomic Tumor Board vs Usual Practice | S2108CD | Y | |||
Y | SWOG | S1912CD CREDIT, Fin Counseling to reduce Fin Hardship | S1912CD | Y | |||
Y | ALLIANCE | A191901 Brst, Text/Motivational Intervention ET Adher | A191901 | Y | |||
ERLYTX | Y | COG | AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult | AGCT1531 | Y | ||
GI | Y | NRG | NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy | NRG-GI004 | Y | ||
Y | ALLIANCE | A021806 Pancreas, Perioperative vs Adjuvant Chemo | A021806 | Y | |||
Y | ALLIANCE | A022102 Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/ Nivo | A022102 | N | |||
Y | ECOG-ACRIN | EA2176 Anal, Met, Immune Check Pt Inhibition + Chemo | EA2176 | N | |||
GU | Y | SWOG | S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum | S1802 | Y | ||
Y | SWOG | S1937 Blad, Mets, Eribulin + Gem vs SOC | S1937 | N | |||
Y | SWOG | S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only | S1931 | N | |||
Y | ALLIANCE | A031704 RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo | A031704 | Y | |||
Y | ECOG-ACRIN | EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT | EA8134 | Y | |||
Y | NRG | NRGGU010 Pros, Parallel De-Intens & Intens Trials | NRG-GU010 | Y | |||
Y | ECOG-ACRIN | EA8191 Pros, Local vs Systemic Thrpy | EA8191 | Y | |||
Y | ECOG-ACRIN | EA8212 Blad, NMIBC, BRIDGE | EA8212 | Y | |||
Y | NRG | NRGGU008 Pros,Node+, Abiraterone acetate + Apalutamide | NRG-GU008 | Y | |||
Y | NRG | NRGGU009 Pros, PREDICT-RT | NRG-GU009 | Y | |||
LEUK | Y | SWOG | S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O | S1925 | Y | ||
Y | ALLIANCE | A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo | A041501 | N | |||
Y | ECOG-ACRIN | EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab | EA9181 | N | |||
LUNG | Y | SWOG | S1827 SCLC, MRI Surveillance +/- PCI | S1827 | Y | ||
Y | SWOG | S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo | S1914 | Y | |||
Y | SWOG | S2302 NSCLC, Stg IV or Recur, Ramu + Pembro vs SoC | S2302 | N | |||
Y | ECOG-ACRIN | E4512 ALCHEMIST2, ALK mut, Crizotinib | E4512 | N | |||
Y | NRG | NRGLU008 Lung NSCL, StgII-III, StereoBodyRad/MedChemo | NRG-LU008 | Y | |||
Y | ALLIANCE | A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO | A081801 | Y | |||
Y | ECOG-ACRIN | EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 | EA5182 | N | |||
LYMPH | Y | ECOG-ACRIN | EA4151 Lymph, AHCT +/-Ritux, MRD Neg | EA4151 | N | ||
Y | ALLIANCE | A052101 Lymph, Stg I-IV, Cont v Intermittent Zanub | A052101 | Y | |||
Y | COG | ANHL1931 PMBCL, Chemo-Immunotherapy +/- Nivo | ANHL1931 | N | |||
Y | COG | AHOD2131 cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy | AHOD2131 | Y | |||
MELAN | Y | ECOG-ACRIN | EA6174 Merkel, Adjuvant Pembrolizumab vs Observation | EA6174 | N | ||
Y | MASC | S2015 MELAN, Stg I-II, 1cm v 2cm excision margins | S2015 | N | |||
MMYEL | Y | SWOG | S1803 MM, Maintenance, Len vs Len/Dara | S1803 | Y | ||
Y | SWOG | S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D | S2209 | Y | |||
Y | SWOG | S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT | S2213 | Y | |||
Y | ECOG-ACRIN | EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) | EAA181 | Y | |||
OTHER | Y | ALLIANCE | N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC | N0577 | N | ||
Y | NRG | NRGBN003 Mening, Grd II, Observation vs Irradiation | NRG-BN003 | Y | |||
Y | COG | AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo | AGCT1532 | Y | Y | ||
Y | COG | ARST2031 RMS, Stg IV, VINO-AC+VINO-CPO vs VAC+VINO-CPO | ARST2031 | N | |||
Y | CCTG | CCTGHN11 HN, All Stg, Guided Elec Contra Neck Tx | CCTG-HN11 | Y | |||
Y | NRG | NRGBN011 Brain, Lomustine + Temo vs Temo | NRG-BN011 | Y | |||
Y | NRG | NRGBN012 Brain, Pre- vs Post-Op Stereotactic Radiosurg | NRG-BN012 | Y | |||
Y | NRG | NRGGY019 Ovar, Stg II-IV, Pac/Carb/Let vs. Let Mono | NRG-GY019 | N | |||
PREV | Y | ECOG-ACRIN | EA1151 Prev, Tomosynthesis Mammographic Screening | EA1151 | N | ||
Y | NRG | NRGCC005 Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs | NRG-CC005 | Y | |||
SURV | Y | SWOG | S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol | S1501 | Y | Y | |
Y | ALLIANCE | A211901 Cancer survivors who smoke, txt cessation | A211901 | Y | |||
SXQOL | NRGCC011 Breast, Survivors, Cog Training | Y | |||||
Y | SWOG | S2010 ASPEN: Brst, Stg I-III, ASM vs Pt Ed | S2010 | Y | |||
Y | SWOG | S2205 ICE COMPRESS: Reduction of CIPN from Taxanes | S2205 | Y | |||
Y | COG | ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis | ACCL1931 | Y | |||
Y | ALLIANCE | A222004 Mult, Olanza vs Megestrol for Anorexia | A222004 | Y | |||
Y | NRG | NRGCC010 Endo, Stg I, LN Map for LE Limb Dysfunction | NRG-CC010 | Y |
Protocol Number |
Study | Accrual Goal |
Open Stat/Date |
Months Open |
Accrual as of 01Jan02 |
Current Accrual | Proj. Annual Accr. Rate |
EXPCLOSE | Proj. Study Duration (Years) |
---|---|---|---|---|---|---|---|---|---|
S1501 S1501 | Surv, Breast Stg IV, Card Tox w/ Carvedilol (SURV) | 817 | T-09/15/17 | 79 | 310 | 310 | 16 | > 15 Yrs | > 15 Yrs |
S1703 S1703 | Met Breast, STM-monitoring v Usual Care (CCD) | 739 | Y-07/16/18 | 69 | 333 | 333 | 60 | Jan-2031 | 12.5 |
S1802 S1802 | Pros, Stg IV, SST +/- Surg/RT to Primary Tum (GU) | 1273 | Y-09/17/18 | 67 | 790 | 790 | 128 | Jan-2028 | 9.4 |
S1803 S1803 | MM, Maintenance, Len vs Len/Dara (MMYEL) | 1100 | Y-06/27/19 | 57 | 1111 | 1111 | 134 | Apr-2024 | 4.8 |
S1827 S1827 | SCLC, MRI Surveillance +/- PCI (LUNG) | 668 | Y-01/10/20 | 51 | 213 | 213 | 60 | Oct-2031 | 11.8 |
S1912CD S1912CD | CREDIT, Fin Counseling to reduce Fin Hardship (CCD) | 326 | Y-07/26/21 | 32 | 227 | 227 | 200 | Sep-2024 | 3.2 |
S1914 S1914 | NSCLC, High Risk Early Stg, SBRT +/- Atezo (LUNG) | 480 | Y-03/25/20 | 49 | 350 | 350 | 160 | Jan-2025 | 4.8 |
S1918 S1918 | DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP (LYMPH) | 422 | Y-03/19/21 | 37 | 96 | 96 | 48 | Jan-2031 | 9.9 |
S1925 S1925 | CLL/SLL, Newly Dx HR, Early vs Delayed V+O (LEUK) | 247 | Y-12/14/20 | 40 | 100 | 100 | 38 | Feb-2028 | 7.2 |
S1931 S1931 | RENAL, Stg IV, IO + Nephrectomy. vs IO Only (GU) | 332 | Y-11/16/20 | 41 | 91 | 91 | 34 | May-2031 | 10.5 |
S1937 S1937 | Blad, Mets, Eribulin + Gem vs SOC (GU) | 184 | Y-02/16/21 | 38 | 27 | 27 | 8 | > 15 Yrs | > 15 Yrs |
S2010 S2010 | ASPEN: Brst, Stg I-III, ASM vs Pt Ed (SXQOL) | 540 | Y-01/17/23 | 15 | 277 | 277 | 338 | Jan-2025 | 2.0 |
S2012 S2012 | Small Cell NEC, Stg IV, Combo Chemo +/- Atezo (ERLYTX) | 189 | Y-12/02/21 | 28 | 44 | 44 | 40 | Nov-2027 | 6.0 |
S2108CD S2108CD | Genomic Tumor Board vs Usual Practice (CCD) | 1182 | Y-08/22/22 | 20 | 952 | 952 | 618 | Aug-2024 | 2.0 |
S2205 S2205 | ICE COMPRESS: Reduction of CIPN from Taxanes (SXQOL) | 777 | Y-03/16/23 | 13 | 127 | 127 | 178 | Nov-2027 | 4.7 |
S2206 S2206 | Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva (BREAST) | 960 | Y-10/30/23 | 5 | 8 | 8 | 16.418629 | > 15 Yrs | > 15 Yrs |
S2209 S2209 | MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D (MMYEL) | 510 | Y-05/30/23 | 10 | 20 | 20 | 38 | Feb-2037 | 13.7 |
S2212 S2212 | Breast, TNBC, Neoadj Chemo + Pembro (BREAST) | 2400 | Y-07/21/23 | 9 | 112 | 112 | 210 | Feb-2035 | 11.6 |
S2213 S2213 | AL Amyloidosis, Newly Dx, Dara-VCD v ASCT (MMYEL) | 338 | Y-12/01/23 | 4 | 0 | 0 | 0 | > 15 Yrs | > 15 Yrs |
S2302 S2302 | NSCLC, Stg IV or Recur, Ramu + Pembro vs SoC (LUNG) | 700 | Y-03/06/23 | 13 | 445 | 445 | 538 | Sep-2024 | 1.6 |
Accrual goals assume studies are not terminated early as a result of interim analysis. Studies may have accrual objectives specific to subsets of patients and are not reflected in this report. Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months. Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months. |